New injection aims to boost meniscus healing after surgery

NCT ID NCT05560477

First seen Jun 25, 2026 · Last updated Jun 25, 2026 · Updated 1 time

Summary

This study tests an injectable drug called AM3101 to see if it can improve healing of meniscus tears in the knee after surgical repair. About 74 people aged 18 to 40 with a torn meniscus will be randomly assigned to receive either AM3101 or a saline placebo during surgery. The trial is double-blinded, meaning neither patients nor doctors know who gets the real drug, and will track healing via MRI and any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENISCUS TEAR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Oregon Health & Science University

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

  • University Hospitals Cleveland Medical Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Cincinnati

    RECRUITING

    Cincinnati, Ohio, 45267, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AM3101 (an injectable drug)

What this could lead to

If it works, this could lead to a treatment that helps meniscus tears heal better after surgery, reducing the need for repeat procedures.

What could go wrong

This is an early phase 1/2b trial with only 74 people, so results may not apply widely. The drug could also cause side effects or not improve healing compared to placebo.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.